Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEZSNASDAQ:CLNNNASDAQ:EGRXNYSE:JATT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.41$3.51$3.96▼$12.00$6.11M1.557,305 shs284 shsCLNNClene$3.87-0.8%$3.44$2.28▼$7.00$35.03M0.5590,346 shs38,466 shsEGRXEagle Pharmaceuticals$3.00+3.6%$2.23$1.50▼$3.00$38.96M0.838,193 shs620 shsJATTJATT Acquisition$1.13+0.9%$1.17$7.80▼$12.38$19.49MN/A41,322 shs129,512 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris0.00%+2.10%-5.54%+40.33%-28.21%CLNNClene-1.65%-1.02%-8.94%+35.31%-44.51%EGRXEagle Pharmaceuticals0.00%+3.45%+33.33%+100.00%-45.45%JATTJATT Acquisition0.00%+7.62%-10.32%+9.71%-67.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEZSAeterna ZentarisN/AN/AN/AN/AN/AN/AN/AN/ACLNNClene2.6406 of 5 stars3.62.00.00.01.82.50.6EGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEZSAeterna Zentaris 0.00N/AN/AN/ACLNNClene 3.17Buy$40.00933.59% UpsideEGRXEagle Pharmaceuticals 0.00N/AN/AN/AJATTJATT Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AEZS, CLNN, EGRX, and JATT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.005/8/2025CLNNCleneBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$84.00 ➝ $33.005/8/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/23/2025CLNNCleneJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.004/8/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/8/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEZSAeterna Zentaris$2.37M2.58N/AN/A$14.99 per share0.23CLNNClene$340K102.21N/AN/A($1.06) per share-3.65EGRXEagle Pharmaceuticals$257.55M0.15$7.50 per share0.40N/A∞JATTJATT AcquisitionN/AN/A$0.04 per share27.08($0.53) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)CLNNClene-$39.40M-$4.04N/AN/AN/A-8,306.00%N/A-105.11%8/6/2025 (Estimated)EGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AJATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/ALatest AEZS, CLNN, EGRX, and JATT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025CLNNClene-$1.10-$0.50+$0.60-$0.09$0.07 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEZSAeterna ZentarisN/AN/AN/AN/AN/ACLNNCleneN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEZSAeterna ZentarisN/A5.945.93CLNNCleneN/A1.361.36EGRXEagle PharmaceuticalsN/AN/AN/AJATTJATT AcquisitionN/A0.150.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEZSAeterna Zentaris0.73%CLNNClene23.28%EGRXEagle Pharmaceuticals85.36%JATTJATT Acquisition47.97%Insider OwnershipCompanyInsider OwnershipAEZSAeterna Zentaris0.10%CLNNClene35.30%EGRXEagle Pharmaceuticals28.90%JATTJATT Acquisition20.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataCLNNClene1008.98 million5.81 millionOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataJATTJATT Acquisition317.25 million13.80 millionNot OptionableAEZS, CLNN, EGRX, and JATT HeadlinesRecent News About These CompaniesCautious Hold Rating on Zura Bio Due to Efficacy Concerns and Competitive RisksDecember 25, 2024 | markets.businessinsider.comZura Bio (ZURA) Receives a Buy from Piper SandlerDecember 12, 2024 | markets.businessinsider.comCautious Outlook on Zura Bio: Neutral Rating Due to Clinical Challenges and Financial UncertaintyNovember 11, 2024 | markets.businessinsider.comThe Legend of Maula Jatt Review: Fawad Khan’s GoT-Coded War Epic Is Derivative, RIdden With ClichesOctober 4, 2024 | moneycontrol.comRelease of Fawad Khan’s Pakistani blockbuster ‘The Legend of Maula Jatt’ halted in IndiaOctober 4, 2024 | thehindu.comPakistani hit The Legend of Maula Jatt, starring Fawad Khan, Mahira Khan, not to release in India, confirms distributorOctober 4, 2024 | hindustantimes.comHIndia puts blockbuster Pakistani film on holdOctober 4, 2024 | bbc.co.uk"What is need to release Pakistani film in India?" Shiv Sena (UBT) opposes release of 'The Legend of Maula Jatt'September 22, 2024 | malaysiasun.comMShiv Sena (UBT) leader Anand Dubey opposes release of Pakistani film 'The Legend of Maula Jatt' in IndiaSeptember 22, 2024 | malaysiasun.comM‘Jatt & Juliet 3’ OTT release: When and where to watch the Diljit Dosanjh and Neeru Bajwa starrer rom-comAugust 27, 2024 | timesofindia.indiatimes.comBahdarpur Jatt Pin CodeApril 9, 2024 | indiatvnews.comINishikant Dubey, wife booked in med college acquisition caseMarch 31, 2024 | timesofindia.indiatimes.comSen. Fetterman says he will use ‘whatever tools are in the box’ to stop Japanese acquisition of U.S. SteelDecember 22, 2023 | pennlive.comPMicrosoft poised to close massive Activision Blizzard acquisition next weekOctober 9, 2023 | vg247.comVThe Legend of Maula Jatt to be released in cinemas on ThursdayJuly 8, 2023 | radio.gov.pkRPakistani film The Legend of Maula Jatt reunites South Asian communities in Antwerp BelgiumJune 15, 2023 | radio.gov.pkRZura Bio's Veteran Leadership Eyes Repeat Success, Confident Analyst Sees 150% UpsideMay 24, 2023 | msn.comI Am A Jaat. People Often Confuse Me For A Jatt. Here’s The Difference Between The TwoApril 28, 2023 | scoopwhoop.comSZura Bio Announces Appointment of Chief Scientific OfficerApril 16, 2023 | businesswire.comTalkTalk, the Issa brothers and AO: The 19 latest deals from across the North WestMarch 30, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEZS, CLNN, EGRX, and JATT Company DescriptionsAeterna Zentaris NASDAQ:AEZS$3.41 0.00 (0.00%) As of 07/3/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Clene NASDAQ:CLNN$3.87 -0.03 (-0.77%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$3.65 -0.22 (-5.66%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Eagle Pharmaceuticals NASDAQ:EGRX$3.00 +0.11 (+3.63%) As of 07/3/2025Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.JATT Acquisition NYSE:JATT$1.13 +0.01 (+0.89%) As of 07/3/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
